IntraBio's only medicine sold $68 million last year. On Monday, Shionogi agreed to pay $2.0 billion in cash for the company that makes it.
The Austin-based biotech was founded in 2015 and has never reported revenue in public. Shionogi disclosed the sales figure itself, inside the announcement of a deal that hands the Japanese group global rights to AQNEURSA (levacetylleucine) and to everything IntraBio is running behind it.
Closing is planned for between November and December 2026. The board approved the agreement on 5 October, and the same day Shionogi said it had not yet worked out what the purchase does to its consolidated results for the fiscal year ending March 2027.
What $2.0 billion actually buys
Shionogi Inc., the New Jersey subsidiary, is buying every outstanding share of IntraBio. All cash. $2.0 billion, with no milestones and no earn-out disclosed. Ownership moves from existing holders — individuals, trusts and corporate entities — to 100% Shionogi Inc.
IntraBio relocated its headquarters to Austin in 2024, when its private valuation was reported at over $1 billion. Monday's price is roughly double that mark, two years on, for a company whose entire commercial output is one small-molecule chaperone therapy.
What that therapy treats changed shape inside a month. The FDA cleared AQNEURSA for neurological manifestations of Niemann-Pick disease type C in September 2024, and the European Medicines Agency followed in January 2026. On 18 September 2026 the FDA approved it again — this time for ataxia in patients with ataxia-telangiectasia, a disease that erodes the cerebellum and kills early. On that indication it is the first and only approved treatment anywhere.
The A-T approval rests on positive Phase 3 results, according to Shionogi. The EMA is still reviewing the same indication in adults and children. The US label covers patients weighing at least 15 kg. Europe's NPC indication runs from age six and 20 kg, taken alongside miglustat or alone when miglustat is not tolerated.
The bull case: buying the position before it erodes
The case for the price begins with how thin the ground under a rare-disease franchise is. AQNEURSA has two indications and $68 million of sales behind it, and it now holds the only approved treatment anywhere for A-T. That is a position, not a pipeline.
Jefferies put peak global sales at up to $1 billion across both indications, against roughly 1,000 potential NPC patients in the US. The arithmetic is unfashionable and stays true: a disease with about a thousand addressable patients in one country supports a nine-figure medicine, and a second label plus an EMA decision widen the base underneath it.
Shionogi bought into the same category seven months ago. In December 2025 it paid $2.5 billion for Tanabe Pharma's global rights to RADICAVA (edaravone) in ALS, plus sales-based royalties, and projected $700 million in annual sales. IntraBio is the second purchase in the same field, from the same buyer, at a comparable price and a comparable stage of commercialisation.
IntraBio also brings a rare-disease commercial organisation: patient identification, reimbursement work, specialty pharmacy distribution, field support in diseases where the treated population is measured in hundreds per country. That infrastructure is the part that generalises. Shionogi has announced three acquisitions in the last year, and this one extends a platform rather than adding an asset to a portfolio.
The planned acquisition of IntraBio actively demonstrates Shionogi's solid commitment to building a leading global rare disease business.— Isao Teshirogi, chief executive, Shionogi & Co.
The bear case: 29 times one product's sales
$2.0 billion against $68 million of revenue is about 29 times sales. Any buyer of assets recognises that instantly. IntraBio is privately held, so the sales number comes from Shionogi's own disclosure rather than a filing that could be checked against it.
One product generates all of it. There is no second commercial medicine and no platform revenue. The A-T label landed 17 days before the announcement and has not yet had a quarter to sell in any jurisdiction.
Shionogi said the effect on its consolidated results for the fiscal year ending March 2027 remains under review. A buyer that cannot yet state what a $2.0 billion cash purchase does to its own accounts is telling you something about where its confidence sits.
Shionogi pays for IntraBio, a company with $68M of 2025 sales
All cash for all outstanding shares, signed 5 October 2026, closing planned November–December · Shionogi, BioSpace, October 2026
The pipeline underneath is real and mostly early. IntraBio runs clinical programmes in Pompe disease, Fragile X syndrome and Jordan's syndrome, adds early-stage rare neurodegenerative work, and lists GM2 gangliosidoses, inherited cerebellar ataxias and CACNA1A-related disorders. It also develops treatments for migraine and dementias, where the commercial logic is a different business entirely.
The 29 times sales multiple only holds if the EMA rules on A-T and NPC uptake both hold. Either one slipping reopens the arithmetic.
Rare-disease infrastructure is bought once and reused across indications. That is why IntraBio's pipeline came with the drug.
What the ultrarare-disease market actually pays for
Aqneursa's regulatory footprint in six months, which is the part Shionogi is buying:
| Indication | Approved | Label |
|---|---|---|
| Niemann-Pick type C | FDA, September 2024 | Adults and children from 15 kg |
| Niemann-Pick type C | EMA, January 2026 | From age 6 and 20 kg, with or without miglustat |
| Ataxia-telangiectasia | FDA, 18 September 2026 | Adults and children from 15 kg |
| Ataxia-telangiectasia | EMA, under review | Adults and children |
Aqneursa approval status as disclosed by Shionogi, 5 October 2026.
Four programmes carry the medium-term argument. Pompe disease is a commercial market with established enzyme therapies. Fragile X and Jordan's syndrome sit in the same ultra-rare commercial infrastructure IntraBio has already built — patient finding, diagnosis, support. The ataxia and lysosomal programmes sit upstream of all of it.
None of that changes what happened on Monday, which is a Japanese company paying cash to own a US rare-disease commercial platform outright, four to six years after a first FDA approval and 17 days after a second one. IntraBio stays whole. No partner, no co-development, no retained management structure beyond the CEO who built it.
What to watch before November
As we wrote in the thyroid-eye orphan field on 8 October, a franchise narrows the moment exclusivity lapses — Tepezza lost its only-drug status in June and every competing claim since has been answered by a larger company that moved first. IntraBio is the other side of that trade. Shionogi is paying $2.0 billion for a company that secured new protection on 18 September, weeks before anyone could test whether it holds.
Three things resolve the question. The EMA decision on A-T sets the size of the second indication. The November or December close decides whether the commercial organisation transfers intact. And Shionogi's own March 2027 reporting will carry the first number that says what $2.0 billion bought.
IntraBio was reported at over $1 billion when it moved to Austin in 2024. On Monday it was bought for twice that, on $68 million of sales and one approval that did not exist three weeks earlier.